These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6288899)

  • 21. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
    Bay JO; Linassier C; Biron P; Durando X; Verrelle P; Kwiatkowski F; Rosti G; Demirer T;
    Int J Cancer; 2007 Apr; 120(8):1782-6. PubMed ID: 17230505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular complications after intracarotid BCNU for intracranial tumors.
    Elsås T; Watne K; Fostad K; Hager B
    Acta Ophthalmol (Copenh); 1989 Feb; 67(1):83-6. PubMed ID: 2549760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
    Levin VA; Hoffman WF; Pischer TL; Seager ML; Boldrey EB; Wilson CB
    Cancer Treat Rep; 1978 Dec; 62(12):2071-6. PubMed ID: 221113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
    Grovas AC; Boyett JM; Lindsley K; Rosenblum M; Yates AJ; Finlay JL
    Med Pediatr Oncol; 1999 Aug; 33(2):83-7. PubMed ID: 10398181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
    Guruangan S; Dunkel IJ; Goldman S; Garvin JH; Rosenblum M; Boyett JM; Gardner S; Merchant TE; Gollamudi S; Finlay JL
    J Clin Oncol; 1998 Jul; 16(7):2486-93. PubMed ID: 9667268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
    Thomas MR; Robinson WA; Glode LM; Dantas ME; Koeppler H; Morton N; Sutherland J
    Am J Clin Oncol; 1982 Dec; 5(6):611-22. PubMed ID: 6762087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
    Levin VA; Wilson CB; Davis R; Wara W; Pischer TL; Irwin L
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1573-6. PubMed ID: 231594
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
    Zulian GB; Selby P; Milan S; Nandi A; Gore M; Forgeson G; Perren TJ; McElwain TJ
    Br J Cancer; 1989 Apr; 59(4):631-5. PubMed ID: 2653400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial ischemia associated with high-dose carmustine infusion.
    Kanj SS; Sharara AI; Shpall EJ; Jones RB; Peters WP
    Cancer; 1991 Nov; 68(9):1910-2. PubMed ID: 1655228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathology of high-dose intraarterial BCNU.
    Kleinschmidt-DeMasters BK; Geier JM
    Surg Neurol; 1989 Jun; 31(6):435-43. PubMed ID: 2541513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cell maneuvers target bone marrow toxicity.
    Randal J
    J Natl Cancer Inst; 1999 Sep; 91(18):1530-2. PubMed ID: 10491422
    [No Abstract]   [Full Text] [Related]  

  • 36. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
    Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
    Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatal veno-occlusive disease of the liver following high-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and autologous bone marrow transplantation.
    McIntyre RE; Magidson JG; Austin GE; Gale RP
    Am J Clin Pathol; 1981 Apr; 75(4):614-7. PubMed ID: 7013473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy with autologous bone marrow rescue: haematopoietic reconstitution by non-cryopreserved marrow.
    Köppler H; Pflüger KH; Havemann K
    Bone Marrow Transplant; 1991; 7 Suppl 2():143. PubMed ID: 1878685
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.